Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study

Scottish Melanoma Group, D A Cameron, M C Cornbleet, R M Mackie, J A Hunter, M Gore, B Hancock, J F Smyth

Research output: Contribution to journalArticlepeer-review


In 1989, the Scottish melanoma group initiated a randomized trial, comparing observation alone with 6 months' therapy with low dose interferon (given subcutaneously 3 MU day-1, twice weekly), for patients with primary melanomas of at least 3 mm Breslow thickness, or with evidence of regional node involvement. The trial was closed in 1993 with only 95 eligible patients randomized. There were no toxic deaths, and no patient failed to complete the treatment for reasons of toxicity. 6 months' treatment with low-dose interferon- resulted in a statistically significant improved disease-free survival for up to 24 months after randomization (P
Original languageEnglish
Pages (from-to)1146-9
Number of pages4
JournalBritish Journal of Cancer
Issue number9
Publication statusPublished - 4 May 2001


  • Adult
  • Antineoplastic Agents
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Drug Administration Schedule
  • Humans
  • Injections, Subcutaneous
  • Interferon-alpha
  • Melanoma
  • Recombinant Proteins
  • Skin Neoplasms


Dive into the research topics of 'Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study'. Together they form a unique fingerprint.

Cite this